Surfactin Like Broad Spectrum Antimicrobial Lipopeptide Co-produced With Sublancin From Bacillus subtilis Strain A52: Dual Reservoir of Bioactives

Deepika Sharma1, Shelley Sardul Singh1, Piyush Baindara1, Shikha Sharma1, Neeraj Khatri1, Vishakha Grover2, Prabhu B. Patil1 and Suresh Korpole*1

1 Council of Scientific and Industrial Research (CSIR) – Institute of Microbial Technology, Chandigarh, India, 2 Dr. Harvansh Singh Judge Institute of Dental Sciences & Hospital, Panjab University, Chandigarh, India

An antimicrobial substance producing strain designated as A52 was isolated from a marine sediment sample and identified as Bacillus sp., based on 16S rRNA gene sequence analysis. The ANI and dDDH analysis of the genome sequence displayed high identity with two strains of B. subtilis subsp. subtilis. Strain A52 yielded two antimicrobial peptides (AMPs) that differed in activity spectrum. MALDI mass spectrometry analysis of HPLC purified fractions revealed mass of peptides as 3881.6 and 1061.9 Da. The antiSMASH analysis of genome sequence unraveled presence of identical biosynthetic cluster involved in production of sublancin from B. subtilis subsp. subtilis strain 168, which yielded peptide with identical mass. The low molecular weight peptide is found to be a cyclic lipopeptide containing C₁₆β-hydroxy fatty acid that resembled surfactin-like group of biosurfactants. However, it differed in fatty acid composition and antimicrobial spectrum in comparison to other surfactins produced by strains of B. subtilis. It exhibited broad spectrum antibacterial activity, inhibited growth of pathogenic strains of Candida and filamentous fungi. Further, it exhibited hemolytic activity, but did not show phytotoxic effect in seed germination experiment. The emulgel formulation of surfactin-like lipopeptide showed antimicrobial activity in vitro and did not show any irritation effects in animal studies using BALB/c mice. Moreover, surfactin-like lipopeptide displayed synergistic activity with fluconazole against Candida, indicating its potential for external therapeutic applications.

Keywords: sublancin, B. subtilis, Candida, synergistic, surfactin-like lipopeptide, emulgel

INTRODUCTION

Development of drug resistance is a great threat to the effective treatment of infections caused by opportunistic or nosocomial pathogens (Davies and Davies, 2010; Prestinaci et al., 2015; Li and Webster, 2018; Laws et al., 2019). Clinically, most significant drug resistant nosocomial pathogens include Staphylococcus aureus, Escherichia coli, Klebsiella spp., Shigella spp., Mycobacterium tuberculosis, Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacter...
spp. (Alanis, 2005; Pande and Bhailume, 2014; Wong et al., 2017). *Candida* is a commensal fungus that is more often associated with infections in immunocompromised individuals. It has been reported to develop resistance to antibiotics like fluconazole, caspofungin, and amphotericin B commonly used to treat candidiasis (Eksi et al., 2013; Lum et al., 2015; Dagi et al., 2016; Ksiezopolska and Gabaldón, 2018). In 2019, Centers for Disease Control and Prevention (CDC) has included drug resistant *Candida* spp. in the list of organisms causing serious threat. In an attempt to combat such resistant pathogens, there is an urgent and compelling need to develop novel antimicrobials. To this effect, antimicrobial peptides (AMPs) including bacteriocins and lipopeptides with broad-spectrum antimicrobial activities have been found to be promising alternative candidates (Singh et al., 2014; Sharma et al., 2014; Lum et al., 2015; Raman et al., 2015; Lyu et al., 2016; Gwynne and Gallagher, 2018).

The genus *Bacillus* is a prolific producer of a wide range of antimicrobials and reported to produce peptide antimicrobial substances like bacteriocins, lipopeptides, and glycopeptides that are active against a variety of bacteria and fungi (Abriouel et al., 2011; Perez et al., 2018; Hashem et al., 2019; Miljkovic et al., 2019). According to their biosynthetic pathways, these bioactive molecules have been grouped mainly into two different classes: the first one comprises ribosomally synthesized peptides usually referred as bacteriocins and classified as ribosomally produced and post-translationally modified peptides (RiPPs) by Arnison et al. (2013). The other class comprises small antimicrobial cyclic lipopeptides synthesized enzymatically by non-ribosomal peptide synthetases (NRPS) and classified as post-ribosomal peptide synthetases (PRPS). Bacteriocins produced by *Bacillus* spp. display a high degree of target specificity against bacterial infections and also a broad spectrum of activity (Abriouel et al., 2011; Herzner et al., 2011; Ramachandran et al., 2014; Wu et al., 2019). Most of the compounds reported from *Bacillus* spp., largely belong to Class I bacteriocins that are known as lantibiotics (Klaenhammer, 1993) or lantipeptides (Arnison et al., 2013). Sublancin is one of such lantipeptide that has an S-linked glycocin produced by *B. subtilis* strain 168. It exhibits antimicrobial activity only against Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA) (Ren et al., 2018; Wang et al., 2018). Other strains of *B. subtilis* were reported to produce lipopeptides mostly pertaining to surfactins, iturins, and fengycins (Zhang and Sun, 2018). However, they differed in antimicrobial activity due to variations in length of fatty acid chains and/or amino acid composition (Mondol et al., 2013; Meena and Kanwar, 2015).

Marine ecosystem is a reservoir of multiple bacterial strains with ability to produce various bioactive compounds for survival (Debbab et al., 2010; Reen et al., 2015; Gupta et al., 2019; Paulsen et al., 2019). The genus *Bacillus* is a predominant microbial flora in marine ecosystem that differed with terrestrial strains in production of diverse classes of AMPs from species like *B. subtilis* (Ivanova et al., 1999; Berrire et al., 2009; Jin et al., 2012; Mondol et al., 2013; Tareq et al., 2014; Chen et al., 2017). Due to advancement in protein purification technology and characterization of AMPs, reports on bioactive from marine bacterial sources have also increased in the recent past. In light of the above facts, we have isolated a *Bacillus* strain from a marine sediment sample and explored the strain A52 for production of antimicrobial compounds, which have been characterized in detail.

**MATERIALS AND METHODS**

**Strain Isolation and Identification**

Strain A52 was isolated from a sediment sample obtained from marine environment (Bay of Bengal, West Bengal, India). During isolation of the bacteria on various media, a colony on nutrient agar (NA, Hi-media, India) with inhibitory zone in their surroundings was sub-cultured on NA and preserved as 20% (v/v) glycerol stocks at −80°C until further studies. All indicator strains used in this study were obtained from Microbial Type Culture Collection and Gene bank (MTCC), Chandigarh, India, and grown on recommended media. Phenotypic properties of strain A52 including morphology, physiology, and biochemical characteristics were performed using standard procedures (Smibert and Krieg, 1994). Identity of the strain was confirmed by BLAST search analysis of 16S rRNA gene sequence (Suresh et al., 2006). Further, taxonomic position of strain was determined by phylogenetic analysis of 16S rRNA gene sequence with the nearest type strains using MEGA version 7 (Kumar et al., 2016). Evolutionary distances were computed by Tamura-Nei method and expressed as units of the number of base substitutions per site to construct a neighbor-joining phylogenetic tree. The strain was further used for whole genome sequence.

**Genome Sequence and Analyses**

Genomic DNA of strain A52 was extracted and libraries were prepared. Sequencing of libraries was done as described earlier (Patil et al., 2016). Quality of obtained reads was checked using FastQC (Patel and Jain, 2012). Reads obtained were assembled using CLC Genomics Workbench 7.5 (CLC bio, Aarhus, Denmark). The average nucleotide identity (ANI) of strain A52 with genome sequences of other closely related members was calculated using ANI calculator (Yoon et al., 2017). Genome to genome distance calculator (GGDC) was used for the estimation of genetic relatedness using GGDC 2.0 web server1 and calculations were performed by recommended formulae 2. Whole genome sequences of reference strains were downloaded from NCBI database in FASTA format. Pangenome analysis was performed using ultra-fast computational pipeline BPGA (Bacterial Pan Genome Analysis tool)2 for core genome analysis.

**Antimicrobial Activity of Strain A52**

The antimicrobial activity was tested by well diffusion assay as mentioned earlier (Singh et al., 2014). Strain A52 was grown for 24 h in 500 ml of nutrient broth (NB, Hi-media, India) using 1000 ml flask and subsequently cells were removed by centrifugation (10,000 rpm for 15 min at 4°C). Supernatant was filtered through 0.22 μm filter (Millipore, United States) to obtain cell-free fermented broth (CFB) that was used for antimicrobial activity.

1http://ggdc.dsmz.de/distcalc2.php

2https://iicb.res.in/bpga/index.html
Production and Purification of Antimicrobial Substances

Production of antimicrobial substances was pursued in NB. However, production was also tested in minimal medium containing (g/l): disodium hydrogen phosphate, 7.9; potassium dihydrogen phosphate, 3.0; sodium chloride, 5.0; and ammonium chloride, 1.0 supplemented with 1% carbon (glucose, sucrose, glycerol, and starch) and nitrogen sources (yeast extract, ammonium chloride, and peptone). Overnight grown culture of strain A52 was inoculated to 1 L of medium and grown to late logarithmic growth phase on a rotary shaker at 30 °C. Subsequently, CFB was mixed with activated Diaion HP-20 (Sigma-Aldrich, United States) resin (2%) and the antimicrobial substance was eluted in methanol. Methanol was evaporated using a rotavapour (BUCHI R-200, Switzerland) and was redissolved in Milli-Q water to offer as crude extract. CFB was also extracted by ethyl acetate solvent extraction using 1:1 ratio (Alajlani et al., 2016). Subsequently, solvent was removed on a rota vapor (BUCHI R-200, Switzerland) and the extract was dissolved in minimal amount of methanol for purification. These extracts were applied onto reverse phase high performance liquid chromatography (HPLC) (1260 Infinity, Agilent Technologies, United States) with a semi-preparative C18 column (Pursuit 10C18 250 mm × 21.2 mm). The solvent system comprised 0.12% aqueous trifluoroacetic acid (TFA, solvent A) and acetonitrile with 0.1% TFA (solvent B). The gradient of solvent B used to run the column was as follows: 0–60% for 0–45 min, 60–80% for 45–50 min, and 80–100% for 50–55 min. Elution from the column was monitored at 220 nm and the peaks of HPLC chromatogram were collected. These fractions were tested for antimicrobial activity and the active peaks were pooled through multiple runs, and solvent was evaporated. Peptides were suspended in water and used for characterization studies like thin layer chromatography (TLC), gel electrophoresis, and MALDI.

In-Gel Activity and TLC Overlay Bioautography

Purified antimicrobial peptides were analyzed on TLC plates (Silica gel 60 F254, Merck, Germany) and used to determine the purity and antimicrobial activity of the compound by bioautographic assay (Zheng et al., 2005). About 50–60 µl of the peptide solution (100 µg/ml concentration) was loaded onto individual TLC silica gel plates in duplicates and were developed using a solvent system containing chloroform: methylene: water (65:12.4: v/v). Subsequently, each TLC plate was dried, cut into two vertical parts, and one part of the TLC was used for direct detection of antimicrobial activity by overlaying on NA plate containing indicator strain (S. aureus MTCC 1430, ~10^6 cells/ml). After allowing for 1 h of diffusion at 4 °C, the TLC strip was removed and plates were incubated for 24 h at 37 °C. The other part of TLC strip (5–10 µl of the peptide solution spot) was sprayed with ninhydrin and phosphomolybdic acid as a staining reagent to detect the presence of peptides and lipid moieties, respectively. Similarly, peptides were electrophoresed on 16% Tricine-SDS-PAGE and used for in-gel activity assay as described earlier (Bandara et al., 2016). S. aureus MTCC 1430 (~10^6 cells/ml) was used as an indicator strain in assay.

Mass Spectrometry of Peptide

HPLC purified peptides and standard surfactin (Sigma, United States) were analyzed using Matrix-Assisted Laser Desorption Ionization (MALDI) to determine intact molecular weights of the peptides. The HPLC purified peptides were re-suspended in water (1 mg/ml) and 1 µl of peptide solution was mixed with 1 µl of matrix (CHCA, 10 mg/ml) and 2.0 µl of this mixture solution was spotted onto the MALDI 100 well stainless steel sample plate, allowed to air dry, and processed for MALDI analysis (AB Sciex 5800 MALDI-time of flight, TOF/TOF). Tandem mass spectrometry (MS/MS) data were acquired at 1,000 Hz in 1 kV MS/MS mode with 2,000 laser shots/spectrum in CID mode as mentioned earlier (Singh et al., 2014). The de novo sequence was generated using fragmentation pattern manually.

Collapse Drop Assay (CDA)

The surfactant property of peptide was determined using the qualitative drop-collapse assay (Youssef et al., 2004). Mineral oil (2 µl) was added to 96-well microtiter plate and equilibrated for 24 h at 37 °C. After equilibration 5 µl of purified peptides (10 µg/ml) were added to the surface of the oil and drop shape was observed after 1 min using magnifying glass. Triton X-100 and water were used as positive and negative control, respectively.

Effect of pH, Temperature, and Proteolytic Enzymes

Sensitivity of purified peptides toward temperature, pH, and non-specific proteases was confirmed by performing bioassays. The pH stability was determined by adjusting the pH 2.0–12.0 of peptide aliquots (using 10 mM HCl or NaOH) and incubating for 4 h at room temperature. Samples were neutralized to pH 7.0 before processing for antimicrobial assay. To determine temperature susceptibility, peptides were incubated at different temperatures ranging from 37 to 100 °C for 1 h and 121 °C for 15 min and residual antimicrobial activity was determined at RT by well diffusion assay. Proteolytic enzymes trypsin and
proteinase K (Sigma, United States) were used at three different concentrations (0.1, 1.0, and 5.0 mg/ml) to observe their effect on the peptide. The enzyme solutions were prepared in 50 mM phosphate buffer (pH 7.0). All reactions were performed at 37°C for 6 h followed by deactivation of enzyme by heating the solution in boiling water for 5 min before performing the activity assay.

**Determination of Minimum Inhibitory Concentration of Peptides**

The minimum inhibitory concentration (MIC) of HPLC purified peptides was evaluated by using microtiter plate dilution assay. The peptide concentration was estimated using BCA protein assay (Thermo Fisher Scientific, United States) method as described by manufacturer. Actively growing test strains were plated on NA. CFU at different time intervals were recorded after 3 days of incubation (Kaur et al., 2016).

**Time Kill Assay**

Purified AMPs were used to perform time kill assay against *S. aureus* MTCC 1430 as mentioned earlier (Baindara et al., 2016). Actively growing bacterial culture (0.2–0.3 OD at 600 nm) was centrifuged (10,000 rpm for 15 min at 4°C) and washed thrice with sterile PBS buffer. The pellet was suspended in PBS and subsequently treated with 2X and 5X MIC values of purified AMPs. Upon incubation for different time intervals, cells were removed from reaction mixture by centrifugation and washed with PBS buffer. Bacterial culture without AMP treatment was used as negative control. Samples were withdrawn at the end of different treatment time points starting from 0 to 8 h, bacterial cells were pelleted, serially diluted, and cell suspensions were plated on nutrient agar plates. For each treatment, negative controls were also processed under identical conditions and plated on NA. CFU at different time intervals were recorded after overnight incubation at 37°C.

**Toxicity Testing**

For hemolysis assay blood was collected from New Zealand white rabbit, centrifuged, washed three times, and resuspended in phosphate-buffered saline (PBS). Cells were counted using hemocytometer (adjusted to 2 × 10^8 cells/ml) and treated with different concentrations of peptides (between 10 and 200 µg/ml). They were incubated in a CO2 incubator for 24 h at 37°C and processed to observe release of hemoglobin as described earlier (Singh et al., 2014). PBS and 0.1% Triton X-100 were used as agents for 0 and 100% hemolysis, respectively.

**Electron Microscopic Studies**

The effect of peptide on cell membrane was determined by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) after treatment with AMPs. For this, test strains *S. aureus* MTCC 1430 and *C. albicans* MTCC 183 were cultured to mid-log phase in respective media. The cells were harvested by centrifugation at 10,000 × g for 10 min, washed thrice with 1X PBS, and re-suspended to adjust an OD of 0.2. The cell suspension was mixed with 2X and 5X MIC of AMPs and incubated at 37°C overnight. Following the incubation, cells were processed for SEM and TEM as described (Raje et al., 2006). The specimens were completely dried using freeze drier, coated with gold, and visualized under a scanning electron microscope (ZEISS, Germany). For TEM (JEOL, JEM 2100, United States), cells were treated with peptide, washed, and subjected to negative stain 0.1% sodium phosphotungstate (Sigma, United States) for visualization. Effect of A52 lipopeptide on fungal spore was observed through a phase contrast microscope (Nikon H600L, Japan).

**Determination of Fractional Inhibitory Concentration**

Fractional inhibitory concentration (FIC) testing was performed to determine the effect of A52 lipopeptide in combination with fluconazole against *C. albicans* MTCC 183. Varying concentrations of fluconazole (0.315–20 µg/ml) and A52 lipopeptide (0.375–12 µg/ml) were used individually or in combination to check the additive effect of antimicrobials. Next, to distinguish between the additive and synergistic effects, we determined the ΣFIC values (Chaturvedi et al., 2011). The interpretation of ΣFIC values was as follows: ≤ 0.5, synergistic; > 0.5 to < 4.0, indifferent (no antagonism), and ≥ 4.0, antagonistic.

**Preparation of Emulgel Formulation**

Gel base was prepared by dispersing carbopol 934 (Hi-media, India) in distilled water with constant stirring at moderate speed for overnight. Oil phase of the emulsion was made with ceteomacrogol 1000, ceteosteryl alcohol, white soft paraffin, propylene glycol in light liquid paraffin (Hi-media, India). Aqueous phase was prepared by dissolving peptides (0.5% w/v) in distilled water. The oily and aqueous phases were separately incubated in a water bath at 60°C. Upon obtaining uniformity, oily phase was added to the aqueous phase with...
continuous stirring. Pre-heated gel base dispersion of carbopol 934 and vitamin ETPGS (Sigma, United States) were added to the emulsion steadily with continuous stirring to obtain homogenized gel. The temperature of the formulation was lowered to 40°C and isopropyl alcohol was added with continuous stirring. The pH was maintained at 6.8 ± 0.2 using saturated solution of citric acid. In vitro emulgel was characterized for its visual appearance under the microscope for the presence of any particle or grittiness. The pH of emulgel was determined by digital pH meter (Contech, India) by dissolving gel in distilled water. Gel extrudability or oozing out from the collapsible tube was determined by physical squeezing from a tube. Gel viscosity was measured using viscometer (Brookfield DV-l Prime, United States).

Skin Irritation Study
Skin irritation potential of lipopeptide based emulgel formulation was evaluated by carrying out skin irritancy test using 8 weeks old BALB/c female mice (Draize et al., 1944). Mice dorsal surface hair was removed without damaging the skin surface about 24 h prior to the experiment. Mice were divided into three groups (n = 3): Group I: 20% sodium lauryl sulfate (SLS) solution (positive control); Group II: plain gel (negative control); and Group III: A52 emulgel. The formulation was topically applied to the hairless skin area (approximately 1 cm²) and observations were recorded at 24, 48, and 72 h. Thus, the applied sites were observed for dermal reactions such as erythema and edema. The mean erythematous and edematous scores were recorded on the basis of their degree of severity caused by application of formulations as follows: no erythema/edema = 0, slight erythema/edema = 1, moderate erythema/edema = 2, and severe erythema/edema = 3.

Statistical Analysis
All results were obtained by performing triplicate experiments in three independent replicates and presented as the mean ± SD (standard deviation). Animal experiments were triplicates performed in two independent replicates. Statistical significance among groups (between treated and untreated groups during killing kinetics and treated and positive control groups during hemolysis) were calculated using student’s t-test. A p-value of 0.05 was considered significant ("p < 0.05, ""p < 0.005, and """"p < 0.0005).

RESULTS

Characterization of Strain A52
A colony on nutrient agar plate showing inhibition activity was isolated and designated as A52. Microscopy examination revealed cells as Gram-positive, rod shaped, motile, and endospore forming. It was catalase positive but methyl red, citrate, and oxidase negative. Optimum growth was observed at 37°C and pH 7. It grew well in the presence of 5% NaCl concentration. Hydrolysis of esculin, starch, gelatin, and tween 20, 40, 60, and 80 was positive. BLAST search of strain A52 showed high identity with type species of B. subtilis subsp. inaquosorum KCTC 13429T (99.93%), B. tequilensis KCTC 13622T (99.93%), and B. subtilis subsp. subtilis NCIB 3610T (99.86%). Neighbor-joining phylogenetic analysis of strain A52 16S rRNA gene resulted in formation of clade with B. subtilis subsp. inaquosorum KCTC 13429T (Figure 1A), consistently. Nonetheless, the ANI and dDHH values obtained for B. subtilis subsp. subtilis NCIB 3610T with strain A52 were found to be 98.43 and 86.00%. This higher identity with B. subtilis subsp. subtilis NCIB 3610T indicates that the strain is pertaining to this subspecies. Similarly, ANI value for the other B. subtilis subsp. spizizenii TUB-10T, B. subtilis subsp. inaquosorum KCTC 13429T, and B. tequilensis KCTC 13622T with A52 were found to be 93.07, 93.01, and 91.63%, respectively. Further, the dDHH values for B. subtilis subsp. spizizenii TUB-10T, B. subtilis subsp. inaquosorum KCTC 13429T, and B. tequilensis KCTC 13622T with A52 were found to be 50.5, 50.10, and 44.9%, respectively. The 16S rRNA gene and draft genome sequences have been deposited at NCBI with accession numbers MT102928 and JACYL000000000, respectively. The pangenome analysis revealed a total number of 3,710 core genes (Figure 1B) amongst all the closest relatives of B. subtilis strains that exhibited highest identity in dDHH. Maximum unique genes (332) were found in strain A52 in comparison to B. subtilis subsp. subtilis NCIB 3610T and strain 168.

Purification and Characterization of A52 Peptides
The CFB obtained from 48 h fermented broth of strain A52 in NB showed promising activity against test strains including bacteria and fungi. Antimicrobial substance production (as measured by inhibition zone) was initiated at mid logarithmic phase (1.5 OD600) and reached to the highest levels at an OD600 of 2.4. Likewise, strain A52 grown in minimal medium containing 1% glucose or sucrose as carbon source yielded the highest inhibition zone of 15 mm against indicator strain, S. aureus. Addition of starch or glycerol and peptone as carbon and nitrogen sources showed moderate antimicrobial production (12 mm). Nevertheless, antimicrobial substance production was comparable in NB (13 mm) and the same was used for large scale production (1 L) as optimized medium. In view of multiple antimicrobial production ability by strains of B. subtilis, the antimicrobial substance from strain A52 was extracted by two methods including Diaion HP-20 resin (reverse phase chromatography, which capture hydrophobic compounds) and ethyl acetate solvent extraction. Crude extracts obtained in both methods displayed presence of major and minor peaks in reverse phase-HPLC analysis. The major fraction collected at 24.6 min (Figure 2A) from Diaion HP-20 extract yielded a single band corresponding to molecular weight of 3 kDa and severe erythema/edema = 3.

Antimicrobial Peptides From B. subtilis Strain A52
signals at m/z 1061.9 and 1084.9 Da (Figure 2D) corresponding to protonated peptide ion [M + H]⁺ and its sodium adduct [M + Na]⁺. It also displayed an isomeric form of lipopeptide with m/z 1064.9 (Supplementary Figure S1A). Both peptides analyzed on TLC were stained with ninhydrin. Peptide with 1061.9 Da mass was also stained with phosphomolybdic acid and tested positive in CDA by exhibiting drop collapse.

**Genome Sequence Analysis**

The 4.22 Mb size draft genome was obtained in 59 contigs with an assembly coverage of ~138X. The G + C content was 43.41 mol%. Analysis of genome sequence using RAST server revealed presence of 4,373 coding sequences (CDS) that contained various gene clusters including those associated with stress and electrolyte homeostasis required for adaptation of marine life, core metabolism, and synthesis of antimicrobial substances. Further, prediction of secondary metabolite biosynthesis gene clusters using antiSMASH identified the presence of eight complete biosynthetic gene clusters involved in synthesis of various antimicrobials secreted by different strains of *B. subtilis* (Table 1). Strikingly, peptide with mass of 3881.6 Da was matched with the mass of an antimicrobial glycocin known as sublancin 168, which showed 100% nucleotide identity with one of the biosynthetic clusters (Figure 3A). The other peptide with mass m/z 1061.9 Da was in agreement to the mass observed for standard surfactin (Supplementary Figure S1B). Consequently, the surfactin encoding non-ribosomal peptide synthetase gene cluster with 82% identity in strain A52 was analyzed in detail (Figure 3B). Furthermore, MS/MS fragmentation pattern resulted in formation of product ion at m/z 705.5, which is presumed to the loss of [Glu¹-Leu/Ile²-Leu³-Val⁴-Asp⁵-Leu⁶-Leu/Ile⁷]⁺ from precursor ion m/z 1061.7 Da (Figure 3C). The de novo sequence hypothesized for surfactin-like lipopeptide was in alignment with the presence of non-ribosomal synthetases encoding 7 amino acids including Glu¹-Leu/Ile²-Leu³-Val⁴-Asp⁵-Leu⁶-Leu/Ile⁷ and a β-OH hexadecane fatty acid chain.

**Minimum Inhibitory Concentration, Killing Kinetics, and FIC**

Sublancin purified from strain A52 showed activity against Gram-positive bacteria including various clinical strains of *Streptococcus* with MIC concentrations ranging between 2 and 10 µg/ml (Table 2). However, growth of few *Bacillus* species like *B. firmus* (MTCC 488), *B. licheniformis* (MTCC 429), *B. thuringiensis* (MTCC 1953) was not inhibited. No activity was detected against *E. coli* MTCC 1610 or fungal test strains. In contrast, surfactin-like lipopeptide showed broad spectrum antibacterial activity. Also, it inhibited all test strains belonging to *Candida* and filamentous fungi (Supplementary Figure S2). The MIC values against bacterial indicator strains were lesser than sublancin (Table 2). Additionally, it was active against fluconazole resistant strains of *Candida* and filamentous fungi with MIC between 12 and 35 µg/ml (Table 2). Bactericidal kinetic
FIGURE 2 | Purification and characterization of antimicrobial peptides. (A) RP-HPLC profile of peptide inset showing Tricine–SDS-PAGE of peptide, TLC stained with ninhydrin and bioautography demonstrating a clear inhibition zone against S. aureus. (B) RP-HPLC profile of lipopeptide inset showing Tricine–SDS-PAGE of lipopeptide, TLC of with Phosphomolybdic acid and bioautography demonstrating a clear inhibition zone against S. aureus. (C) MALDI analysis of peptide. (D) MALDI analysis of lipopeptide.

TABLE 1 | Different secondary metabolite clusters present in strain A52 and its closely related spp. (1) Strain A52, (2) B. subtilis subsp. subtilis strain 168, (3) B. subtilis subsp. spizizenii strain TUB-10, (4) B. subtilis subsp. inaquosorum KTCC 13429, (5) B. tequilensis KTCC 13622.

| S. No. | Antimicrobial peptides | Class of antimicrobials | 1 | 2 | 3 | 4 | 5 | Peptide mass (Da) | References |
|-------|------------------------|------------------------|---|---|---|---|---|----------------|------------|
| 1     | Subtilosin A           | Sactipeptide           | + | + | + | + | + | 3015.5          | Babasaki et al., 1985 |
| 2     | Bacilysin              | NRPS dipeptide         | + | + | + | + | + | 271.1           | Phister et al., 2004 |
| 3     | Subtilin               | Lanthipeptide          | + | − | + | − | − | 3321.7          | Parisot et al., 2008 |
| 4     | Bacillibactin          | Siderophore            | + | + | + | + | + | 881.2           | May et al., 2001     |
| 5     | Sublancin 168          | Lanthipeptide          | + | + | − | − | − | 3880.7*         | Oman et al., 2011    |
| 6     | Bacillaene             | Polyene antibiotic     | + | + | + | + | + | 581.3           | Butcher et al., 2007 |
| 7     | Fengycin               | Lipopeptide            | + | + | − | + | + | 1443.7          | Villegas-Escobar et al., 2013 |
| 8     | Surfactin              | Lipopeptide            | + | + | + | + | + | 1058.6          | Villegas-Escobar et al., 2013 |

*Molecular weight of reduced peptide.

studies of sublancin A52 (5X MIC) using cells of S. aureus MTCC 1430 revealed reduction of bacterial load completely after 8 h of treatment (Figure 4A) whereas lipopeptide (5X MIC) showed complete killing of S. aureus MTCC 1430 within 7 h of treatment (Figure 4B). No reduction in CFU count was noticed for negative controls. A combination of the surfactin-like lipopeptide and fluconazole was found to reduce MIC of fluconazole against C. albicans MTCC 183. Remarkably, the treatment in combination led to four times decrease in the MIC of fluconazole in the presence of A52 surfactin-like lipopeptide (Figure 4C), suggesting their combinatorial effect to be synergistic (Σ FIC = 0.375).

**Temperature and Enzyme Sensitivity**

Sublancin from strain A52 was found to be stable up to 70°C and lost activity completely after autoclaving. It was also stable between pH 4.0 and 10.0. On the other hand, antimicrobial activity of the surfactin-like lipopeptide from strain A52 was not affected upon exposure to 100°C, but retained 89.0% activity after autoclaving (121°C for 15 min). It was found to be stable between
pH 4.0 and 10.0, however, complete loss in activity was noticed at pH 2.0 and 11.0. Studies on tolerance of the peptide to proteolytic enzymes revealed that both peptides were resistant to trypsin and proteinase K treatment (Supplementary Table S1). Additionally, lipopeptide was found to be stable to lipase treatment.

**Microscopic Examination of Pathogens After Peptides Treatment**

The images of untreated *S. aureus* cells showed smooth cell surface and appeared to be healthy and intact. The sublancin A52 treated cells showed altered morphology and shrinkage in TEM images, whereas the surfactin-like lipopeptide treated cells showed cell wall irregularities such as wall rupturing and cellular lysis (Figures 5A,B). Similarly, SEM images of surfactin-like lipopeptide treated *C. albicans* cells showed structural irregularity with disintegrated outer cell membrane resulting in dispersion of the intracellular contents while the control cells showed complete cell membrane and homogeneous cytoplasm (Figure 5C).

**Hemolysis and Phytotoxicity**

Sublancin from strain A52 did not show any hemolytic activity even at the 5X MIC concentration (Figure 6A) but surfactin-like lipopeptide demonstrated hemolytic activity at 1X MIC concentration (Figure 6B), which is almost equivalent to the activity shown by 1% Triton X-100. Surfactin-like lipopeptide was also able to lyse the spores formed by phytopathogenic fungus *A. brassicicola* MTCC 2102 (Figure 6C). It did not exhibit phytotoxicity in seed germination assay against *Vigna radiata*.
TABLE 2 | MIC values of surfactin-like lipopeptide and sublancin from strain A52 against various test strains of bacteria, yeast, and filamentous fungi.

| S. No. | Test organism | Strain number | MIC value (µg/ml) | Fluconazole* | Amphotericin B* | Ampicillin† | Lipopeptide A52 | Sublancin# |
|--------|---------------|---------------|------------------|--------------|----------------|-------------|----------------|------------|
| Yeast  |               |               |                  |              |                |             |                |            |
| 1      | C. albicans   | MTCC 183      | 20               | 5            | –              | 12          | –              | –          |
| 2      | C. albicans   | MTCC 1637     | R                | 5            | –              | 28          | –              | –          |
| 3      | C. albicans   | MTCC 227      | R                | 5            | –              | 24          | –              | –          |
| 4      | C. tropicalis | MTCC 184      | R                | 35           | –              | 12          | –              | –          |
| 5      | C. glabrata   | MTCC 3019     | R                | 25           | –              | 16          | –              | –          |
| 6      | C. haemulonii | MTCC 2766     | R                | 100          | –              | 20          | –              | –          |
| 7      | C. inconspicue| MTCC 1074     | 50               | 10           | –              | 16          | –              | –          |
| Clinical Isolates |               |               |                  |              |                |             |                |            |
| 8      | C. auris      | 470126        | R                | 5            | –              | 26          | –              | –          |
| 9      | C. rugos      | 470141        | 5                | 5            | –              | 16          | –              | –          |
| 10     | C. kefyr      | 410004        | R                | 50           | –              | 26          | –              | –          |
| 11     | C. krusei     | 440009        | 1                | 5            | –              | 16          | –              | –          |
| 12     | C. albicans   | 400054        | R                | 5            | –              | 16          | –              | –          |
| 13     | C. tropicalis | 420024        | R                | 50           | –              | 28          | –              | –          |
| 14     | C. parasitosis| 450030        | 10               | 50           | –              | 28          | –              | –          |
| 15     | C. glabrata   | SKSS ID       | R                | 100          | –              | 16          | –              | –          |
| 16     | C. haemulonii | 470125        | R                | 50           | –              | 28          | –              | –          |
| Fungus |               |               |                  |              |                |             |                |            |
| 17     | A. brassicola | MTCC 2102     | R                | 50           | –              | 25          | –              | –          |
| 18     | C. acutatum   | MTCC1037      | R                | R            | –              | 35          | –              | –          |
| 19     | F. moniliforme| MTCC 158      | 10               | 50           | –              | 20          | –              | –          |
| Bacteria |             |               |                  |              |                |             |                |            |
| 20     | S. aureus     | MTCC 1430     | –                | –            | 0.25           | 4           | 10             | –          |
| 21     | B. subtilis   | MTCC 121      | –                | –            | 0.50           | 2           | 5              | 5          |
| 22     | B. cereus     | MTCC 430      | –                | –            | 0.50           | 2           | 5              | 5          |
| 23     | B. coagulans  | MTCC 492      | –                | –            | 0.50           | 2           | 8              | 8          |
| 24     | S. pyogenes   | MTCC 1928     | –                | –            | 0.03           | 2           | 2              | 2          |
| 25     | S. anginosus  | MTCC1929      | –                | –            | 0.25           | 4           | 6              | 6          |
| 26     | S. oralis     | MTCC 2696     | –                | –            | 0.40           | 4           | 8              | 8          |
| 27     | S. mutans     | MTCC 497      | –                | –            | 0.40           | 6           | 10             | 10         |
| 28     | M. luteus     | MTCC 106      | –                | –            | 0.20           | 1           | 2              | 2          |
| 29     | E. coli       | MTCC 1610     | –                | –            | 1.0            | 6           | –              | –          |

*Antifungal compounds that have no activity against bacteria. †Antibacterial broad spectrum. #Reported as narrow spectrum antibiotic by Paik et al. (1998). $Each test done in triplicate and optical density (OD$_{600}$) of antimicrobial peptide treated wells were compared with uninoculated wells (blank medium control).

(Moong) seeds even at 60 µg/ml concentration. Indeed, there was no difference observed in germination and seedling formation between test and control (Figure 6D).

Emulgel Formulation and Properties

For preparation of emulgel, 50 mg of surfactin-like lipopeptide was dissolved in water and added to 10 g of emulgel formulation to make a final concentration of 0.5% w/w. The optimized chemical composition (%) used in the preparation of emulgel was propylene glycol (15.0%), cetomacrogol 1000 (2.5%), cetostearyl alcohol (7.5%), white soft paraffin (10.0%), liquid paraffin (2.5%), vitamin E TPGS (5.0%), carbopol 934 (0.5%), isopropyl alcohol (1.0%), and water (55.5%). In vitro assessment of emulgel formulation containing surfactin-like lipopeptide exhibited activity against M. luteus MTCC 106 and C. albicans MTCC 183 (Supplementary Figure S3). Individual testing of the above compounds at employed concentrations did not show antimicrobial activity against test strains. The emulgel was opaque and creamish in its appearance. The pH of emulgel was found to be 6.8 ± 0.2 and showed good extrudability. The viscosity of emulgel containing 0.5% w/w of carbopol was found to be 1451cP.

Skin Irritation Study

Results of skin irritancy of surfactin-like lipopeptide containing emulgel formulation determined using Draize test are summarized in Supplementary Table S2. The emulgel did not show any type of irritation as observed at time intervals of 24, 48, and 72 h after application. Dryness, hardening, and redness of skin was noticed at the site of SLS application which is known to cause irritation (Figure 7A). No effect was detected in negative control (Figure 7B). The results of emulgel formulation
application on skin was found to be similar with negative control (Figure 7C). There were no irritation symptoms observed even after 72 h upon application.

**DISCUSSION**

Increased resistance to antibiotics has resulted in difficulty to eliminate nosocomial and chronic infections. In the quest to develop novel antimicrobial agents, the marine ecosystem is favored environmental niche owing to the presence of diverse antimicrobial substances (Desjardine et al., 2007; Bainsdara et al., 2013; Ponnappan et al., 2015; Agrawal et al., 2017; Gupta et al., 2019). Therefore, in this study, we have explored a marine sediment bacterial isolate for antimicrobial production ability. Strain A52 was identified as a member of the genus *Bacillus*, taxonomically related to species *B. subtilis* (Tareq et al., 2014) and *B. tequilensis* (Rani et al., 2016). The ANI and dDDH of A52 genome sequence showed highest identity with *B. subtilis* subsp. *subtilis* NCIB 3610\(^T\) and followed by strain 168 (98.4 and 85.9%, respectively). Strain A52 mainly differed with both strains in number of unique genes, mostly involved in adaptation to marine environment. RAST, and bioinformatics analyses of genome sequence revealed the ability of strain A52 to produce multiple antimicrobials. Thus, strain A52 was grown in the presence of different carbon and nitrogen sources to test the possibility of multiple antimicrobials production as mentioned in Table 1. Since crude extract inhibited the growth of indicator strains pertaining to Gram-positive, Gram-negative bacteria, and *Candida*, we have analyzed the extract (including extracts from NB and MM with 1% glucose) on HPLC and detected the presence of two compounds with different spectrum of

---

**FIGURE 4** | Antimicrobial peptide mediated growth inhibition studies. (A) Killing kinetics of sublancin A52 (2X and 5X MIC) against *S. aureus* MTCC 1430. (B) Killing kinetics of surfactin-like lipopeptide (2X and 5X MIC) against *S. aureus* MTCC 1430. (C) The heat-map showing combination of surfactin-like lipopeptide from A52 and fluconazole inhibitory activity against indicator strain *C. albicans* MTCC 183. Addition lipopeptide (0.75 \(\mu\)g/ml) led to fourfold (2.5 \(\mu\)g/ml) decrease in MIC of fluconazole. The heat-map was generated using the morpheus software. \(* p < 0.05, \** p < 0.005, and \*** p < 0.0005.\)
antimicrobial activity. Both purified compounds analyzed on TLC were stained with ninhydrin, indicating possible peptide nature of compounds. The low molecular weight compound stained with phosphomolybdic acid yielding a bluish black band, exposed association of a lipid group with the peptide. Lipopeptide presence was also confirmed with the increased surface diameter in collapse drop assay.

The validated mass of 3881 Da as detected for peptide from strain A52 is in alignment with the mass 3880.78 Da of reduced sublancin, a glycocin antimicrobial peptide produced by closest relative B. subtilis strain 168 (Oman et al., 2011; Wang et al., 2017). The reduced nature of peptide in this study is assumed to be due to the presence of acetonitrile in 0.1% TFA (Erlandsson and Hallbrink, 2005) as the peptide was not freeze dried to remove the solvent upon HPLC purification. The minor difference in mass may be due to instrument error (50 ppm deviation). Since sublancin belongs to the class of glycocins, which contains an unusual and essential glucosylated Cys residue (Gonzalo et al., 2014; Ji et al., 2015; Wang et al., 2017; Wu et al., 2019), we have verified the presence of sugar residue using α-naphthol reagent and confirmed the peptide as sublancin. Furthermore, the peptide inhibited the growth of only Gram-positive bacteria as described for sublancin (Oman et al., 2011). Number of Gram-positive test strains used for antimicrobial assay showed the ability of sublancin to kill various species of the genus Bacillus with few exceptions owing to the fact that sensitivity of various strains to the same bacteriocin is highly variable (Rasch and Knöchel, 1998). Sublancin is also reported to inhibit growth of methicillin resistant Staphylococcus aureus (MRSA) and showed protective ability in mice infection studies (Wang et al., 2017). TEM imaging of S. aureus cells treated with sublancin from A52 provided clear evidence that it possesses
bactericidal activity without cell lysis (Figure 5A), which is in accordance with recently studied mode of action of sublancin that reported negative effect on DNA replication, transcription, and translation (Wu et al., 2019). The thermal stability, broad pH range, and resistance to proteinase K and trypsin are in accordance with results observed earlier (Ji et al., 2015).

Likewise, the antiSMASH analysis for strain A52 genome sequence highlighted presence of a NRPS encoding genes with 82% nucleotide sequence identity to biosynthetic gene cluster involved in surfactin biosynthesis. As shown in mass spectrometry lipopeptide has a molecular weight of 1061 Da, which falls within the range of observed mass for surfactants. Combining the data from genes encoding NRPS clusters and mass obtained, we hypothesized that the lipopeptide consists of 7 amino acids as shown by the presence of specific synthetases which are commonly found in surfactin biosynthesis (Ma et al., 2016; Chen et al., 2017). The fatty acid moiety was identified as β-OH palmitic acid chain that has not been reported in surfactins produced by B. subtilis strains. Unlike other surfactins, the lipopeptide was found to be highly thermostable as it retained activity even after autoclaving. No reduction in activity was observed upon incubation with proteases or lipase. These results are in line with earlier reported lipopeptide properties in literature (Sharma et al., 2014; Jha et al., 2016; Chen et al., 2017).

Strikingly, surfactin-like lipopeptide produced by strain A52 showed broad spectrum antimicrobial activity against bacteria at low concentrations. Though inhibition of phytopathogenic fungi required higher concentrations, it was less than 25 μM that is generally employed to screen antifungal peptides and lipopeptides (Mircus et al., 2015). Earlier reports show that antimicrobial spectrum of lipopeptides were purely dependent on the length of their fatty acid moiety (Strieker and Marahiel, 2009; Mandal et al., 2013; Meir et al., 2017). Thus, it is pertinent to mention that the presence of different fatty acid resulted in broad spectrum antibacterial, anticandidal, and antifungal activities. SEM and TEM imaging of surfactin-like lipopeptide treated cells showed disruption of membrane due to possible pore formation resulting in scattering of cellular contents in their surroundings (Figure 5). This membrane lysis mechanism of action of lipopeptides makes the pathogens highly susceptible by decreasing the ability to develop resistance (Mangoni and Shai, 2011). In fact, surfactant-like lipopeptide was able to inhibit fluconazole resistant Candida by lowering the MIC of fluconazole in a synergistic combination. These results suggest that combined usage of the active compound with existing drugs shall contribute toward lowering the adverse effects associated with antifungal agents, while maintaining the effectiveness of the drug.
For commercial application of biologically active compounds, it is imperative to explore their toxigenic potential for the relevant applications. Though lipopeptides cause hemolysis (Inès and Dhouha, 2015; Greber et al., 2018; Ramachandran et al., 2018), surfactin-like lipopeptide in this study showed promising potential for topical applications as evident from the emulgel experiment. The gel showed antimicrobial activity and did not show any skin irritation effect during experiment with BALB/c mice. Further, it was explored for phytotoxicity, where it showed no adverse effects in the seed germination process. Thus it may be developed as a crop-protective agent for use in agriculture field, but only upon detailed experiments, which are beyond the scope of this study. Considering broad activity with low MIC values and thermos-stability, surfactin-like lipopeptide secreted by strain A52 was found to be an appealing candidate for potential application as a topical therapeutic agent.

**CONCLUSION**

A novel broad spectrum antifungal lipopeptide has been reported from *B. subtilis* strain A52 isolated from marine sediment. It is simultaneously expressed with a well-known bacteriocin sublancin. The 1061.9 Da surfactin-like lipopeptide is highly effective against a diverse array of human and plant pathogenic fungi and has a broad spectrum antibacterial activity. Essentially, surfactin-like lipopeptide has shown synergistic activity with contemporary antifungal agent fluconazole, suggesting its promising role as a topical therapeutic agent.

**DATA AVAILABILITY STATEMENT**

The datasets generated for this study can be found in the genome sequence accession no. JAACYL000000000 and 16S rRNA gene sequence accession no. MT102928.

**ETHICS STATEMENT**

The animal study was reviewed and approved by the Institutional Animal Ethics Committee, Committee for the Purpose of Control and Supervision of Experiments on Animals approval no. 18/08.
AUTHOR CONTRIBUTIONS

DS, SS, NK, and SK designed experiments. DS, SSS, PB, SS, PBP, NK, and SK performed experiments. DS, SSS, VG, PBP, and SK analyzed data. DS, SSS, VG, and SK prepared the manuscript.

FUNDING

This research was supported by grants from the Department of Science and Technology (DST), New Delhi, India (DS fellowship SR/WOS-A/LS-220/2017), SERB, DST, and CSIR, Government of India.

REFERENCES

Abriouel, H., Franz, C. M., Omar, N. B., and Galvez, A. (2011). Diversity and applications of Bacillus bacteriocins. FEMS Microbiol. Rev. 35, 201–232. doi: 10.1111/j.1574-6976.2010.00244.x
Agrawal, S., Acharya, D., Adholeya, A., Barrow, C. J., and Deshmukh, S. K. (2017). Nonribosomal peptides from marine microbes and their antimicrobial and anticancer potential. Front. Pharmacol. 8:828. doi: 10.3389/fphar.2017.00828
Alajlani, M., Sheikh, A., Hasnain, S., and Brantner, A. (2016). Purification of bioactive lipopeptides produced by Bacillus subtilis strain BLA. Chromatographia 79, 1527–1532. doi: 10.1007/s00716-016-3164-3
Alanis, A. J. (2005). Resistance to antibiotics: Are we in the post-antibiotic era? Arch. Med. Res. 36, 697–705. doi: 10.1016/j.arcmed.2005.06.009
Arimson, P. G., Bubb, M. J., Bierbaum, G., Bowers, A. A., Bugni, T. S., Bulaj, G., et al. (2013). Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat. Prod. Rep. 30, 108–160. doi: 10.1039/c2np20085f
Babasaki, K., Takao, T., Shimomishi, Y., and Kurahashi, K. (1985). Subtilosin A, a new antibiotic peptide produced by Bacillus subtilis 168: isolation, structural analysis, and biogenesis. J. Biochem. 98, 585–603. doi: 10.1093/oxfjdjournals.jbc.135.315
Baindara, P., Chaudhry, V., Mittal, G., Liao, I. M., Matos, C. O., Khatri, N., et al. (2016). Characterization of the antimicrobial peptide penisin, a class Ia lantibiotic from Paenibacillus sp. strain A3. Antimicrob. Agents Chemother. 60, 580–591. doi: 10.1128/AAC.01813-15
Baindara, P., Mandal, S. M., Chawla, N., Singh, P. K., Pinnaka, A. K., and Korpole, S. (2013). Characterization of two antimicrobial peptides produced by a halotolerant Bacillus subtilis strain SK. DU. 4 isolated from a rhizosphere soil sample. AMB Express 3:2. doi: 10.1186/2191-0855-3-2
Berrue, F., Ibrahim, A., Boland, P., and Kerr, R. G. (2009). Newly isolated marine Bacillus pumilus (SP21): a source of novel lipodepsipeptides and other antimicrobial agents. Pure Appl. Chem. 81, 1027–1031. doi: 10.1351/PAC-CON-08-09-25
Butcher, R. A., Schroeder, F. C., Fischbach, M. A., Straight, P. D., Kolter, R., Walsh, C. T., et al. (2007). The identification of baceilamet, the product of the PksX megacomplex in Bacillus subtilis. Proc. Natl. Acad. Sci. U.S.A. 104, 1506–1509. doi: 10.1073/pnas.0610531014
Chaturvedi, A. K., Engels, E. A., Pfifer, R. M., Hernandez, B. Y., Xiao, W., Kim, E., et al. (2011). Human papillomavirus and rising oropharyngeal cancer incidence and antifungal susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. Sci. World J. 2013:236903. doi: 10.1155/2013/236903
Davies, J., and Davies, D. (2010). Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433. doi: 10.1128/MMBR.00016-10
Debbab, A., Aly, A. H., Lint, W. H., and Proksch, P. (2010). Bioactive compounds from marine bacteria and fungi. Microb. Biotechnol. 3, 544–563. doi: 10.1111/j.1574-6976.2010.00179.x
Desjardine, K., Pereira, A., Wright, H., Matainaho, T., Kelly, M., and Andersen, R. J. (2007). Tauramamide, a lipopeptide antibiotic produced in culture by Brevibacillus laterosporus isolated from a marine habitat: structure elucidation and synthesis. J. Nat. Prod. 70, 1850–1853. doi: 10.1021/np070209r
Draize, J. H., Woodard, G., and Calvery, H. O. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J. Pharmacol. Exp. Ther. 82, 377–390.
Eksi, F., Gayyurhan, E. D., and Balci, I. (2013). In vitro susceptibility of Candida species to four antifungal agents assessed by the reference broth microdilution method. Sci. World J. 2013:236903. doi: 10.1155/2013/236903
Gonzalo, G. D. C. V., Zhu, L., Oman, T. J., and van der Donk, W. A. (2014). NMR structure of the S-linked glycopeptide sublancin 168. Chem. Biol. 9, 796–801. doi: 10.1016/cb008106
Greber, K. E., Ciura, K., Belka, M., Kawczak, P., Nowakowska, J., Bączek, T., et al. (2018). Characterization of antimicrobial and hemolytic properties of short synthetic cationic lipopeptides based on QSAR/QSTR approach. Amino Acids 50, 479–485. doi: 10.1007/s00726-017-2530-2
Gupta, V., Singh, S. S., Sidhu, C., Grover, V., Pinnaka, A. K., and Korpole, S. (2019). Virginic, a novel lantipeptide from Virgibacillus sp. strain AK90 exhibits inhibitory activity against Gram-positive bacteria. World J. Microbiol. Biotechnol. 35:133. doi: 10.1186/s11274-019-2707-9
Gwernne, P. J., and Gallagher, M. P. (2018). Light as a broad-spectrum antimicrobial. Front. Microbiol. 9:119. doi: 10.3389/fmicb.2018.00119
Hashem, A., Tabassum, B., and Allah, E. F. A. (2019). Bacillus subtilis: a plant-growth promoting rhizobacterium that also impacts biostress. Saudi J. Biol. Sci. 26, 1291–1297. doi: 10.1016/j.sjbs.2019.05.004
Herzner, A. M., Dusching, J., Stekat, C., Josten, M., Schmitz, S., Yakélva, A., et al. (2011). Expression of the lantibiotic mersacidin in Bacillus amyloliquefaciens FZB42. PLoS One 6:e22389. doi: 10.1371/journal.pone.0022389
Inés, M., and Dhouha, G. (2015). Lipopeptide surfactants: production, recovery and pore forming capacity. Peptides 71, 100–122. doi: 10.1016/j.peptides.2015.07.006
Ivanova, E. P., Vysotskii, M. V., Svetashov, V. I., Nedashkovskaya, O. I., Gorshkova, N. M., Mikhailov, V. V., et al. (1999). Characterization of Bacillus strains of marine origin. Int. Microbiol. 2, 267–271.
Jha, S. S., Joshi, S. J., and Geetha, S. J. (2016). Lipopeptide production by Bacillus subtilis R1 and its possible applications. Braz. J. Microbiol. 47, 955–964. doi: 10.1016/bjm.2016.07.006
Ji, S., Li, W., Baloch, A. R., Wang, M., and Cao, B. (2015). Improved production of sublancin via introduction of three characteristic promoters into operon

ACKNOWLEDGMENTS

We acknowledge the help of Dr. Lakhvir Kaur (Asst. Prof.), Department of Pharmaceutics Khalsa College of Pharmacy, Amritsar (India), for providing viscosity data of emulgel. We acknowledge technical help from Ms. Megha Sharma and we thank Dr. S. M. Mondal for standard surfactin analysis.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.01167/full#supplementary-material
clusters responsible for this novel distinct glycopeptide biosynthesis. Microb. Cell. Fact. 14:17. doi: 10.1186/s12934-015-0201-0

Jin, X. B., Sun, R. J., Zhu, J. Q., Xu, Z. J., Liu, Z., Wang, Q., et al. (2012). Isolation and identification of Bacillus altitudinis Z1 186 from marine soil samples and its antifungal activity against Magnaporthe grisea. Curr. Res. Bacteriol. 5, 13–23. doi: 10.3923/crb.2012.13.23

Kaur, T., Kaur, A., Sharma, V., and Manhas, R. K. (2016). Purification and characterization of a new antifungal compound 10-(2, 2-dimethyl-cyclohexyl)-6, 9-dihydroxy-4, 9-dimethyl-dec-2-enolic acid methyl ester from Streptomyces hydrogenans strain DH16. Front. Microbiol. 7:1004. doi: 10.3389/fmicb.2016.01004

Kleinhäuser, T. R. (1993). Genetics of bacteriocins produced by lactic acid bacteria. FEMS Microbiol. Rev. 12, 39–86.

Kiseczpolka, E., and Gabaldón, T. (2018). Evolutionary emergence of drug resistance in Candida opportunistic pathogens. Genes 9:461. doi: 10.3390/genes9040461

Kumar, S., Stecher, G., and Tamura, K. (2016). MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol. Biol. Evol. 33, 1870–1874. doi: 10.1093/molbev/msw054

Laws, M., Shaaban, A., and Rahman, K. M. (2019). Antibiotic resistance breakers: current approaches and future directions. FEMS Microbiol. Rev. 43, 490–516. doi: 10.1093/femsec/fiz014

Li, B., and Webster, J. T. (2018). Bacteria antibiotic resistance: new challenges and opportunities for implant-associated orthopedic infections. J. Orthop. Res. 36, 22–32. doi: 10.1002/jor.23656

Lum, K. Y., Tay, S. T., Lee, C. F., Lee, V. S., Sabri, N. H., Velayuthan, R. D., et al. (2015). Activity of novel synthetic peptides against Candida albicans. Sci. Rep. 5:9657. doi: 10.1038/srep09657

Lyu, Y., Yang, Y., Lyu, X., Dong, N., and Shan, A. (2016). Antimicrobial activity improved cell selectivity and mode of action of short PMAP-36-derivative peptides against bacteria and Candida. Sci. Rep. 6:27258. doi: 10.1038/srep27258

Ma, Y., Kong, Q., Qin, C., Chen, Y., Chen, Y., Lv, R., et al. (2016). Identification of lipopeptides in Bacillus megaterium by two-step ultrafiltration and LC-ESI/MS/MS. AMB Express 6:79. doi: 10.1186/s13568-016-0252-6

Mandal, S. M., Sharma, S., Pinnaka, A. K., Kumari, A., and Korpole, S. (2013). Isoflavonoids from marine strains of genus Stenotrophomonas. Front. Microbiol. 7:309. doi: 10.3389/fmicb.2016.00309

Paulsen, S. S., Strube, M. K., Beck, P. K., Gram, L., and Sonnenschein, E. C. (2019). Marine chitinolytic Pseudomonas aeruginosa represents an untapped reservoir of bioactive potential. mSystems 4:e00060-19. doi: 10.1128/mSystems.00060-19

Perez, R. H., Zendo, T., and Sonomoto, K. (2018). Circular and leaderless bacteriocins: biosynthesis, mode of action, applications, and prospects. Front. Microbiol. 9:2085. doi: 10.3389/fmicb.2018.02085

Phister, T. G., O’ Sullivan, D. J., and McKay, L. L. (2004). Identification of Bacilysin, Chlorotetaine, and Itririn A produced by Bacillus sp. Strain CS93 isolated from Pozol, a Mexican fermented maize dough. Appl. Environ. Microbiol. 70, 631–634. doi: 10.1128/AEM.70.1.631-634.2004

Ponnappan, N., Budagavi, D. P., Yadav, B. K., and Chugh, A. (2015). Membrane-active peptides from marine organisms-antimicrobials, cell-penetrating peptides and peptide toxins: applications and prospects. Probiotics and Antimicrob. Proteins 7, 75–89. doi: 10.1007/s12602-014-9182-2

Prestinaci, F., Pezzotti, P., and Pantosti, A. (2015). Antimicrobial resistance: a global multifaceted phenomenon. Pathog. Glob. Health 109, 309–318. doi: 10.1179/204773215Y.0000000030

Raje, M., Dhiman, R., Majumdar, S., Dass, T., Dikshit, K. L., and Kaur, R. (2006). Charged nylon membrane substrate for convenient and versatile high resolution mass-spectrometric analysis of Escherichia coli and mammalian cells in suspension culture. Cytotechnology 51, 111–117. doi: 10.1007/s10616-006-9027-2

Ramachandran, R., Chalasani, A. G., Lal, R., and Roy, U. (2014). A broad-spectrum antimicrobial activity of Bacillus subtilis RLID 12.1. Sci. World J. 2014:968487. doi: 10.1155/2014/968487

Ramachandran, R., Shrivastava, M., Narayanan, N. N., Thakur, R. L., Chakraborti, A., and Roy, U. (2018). Evaluation of antifungal efficacy of three new cyclic lipopeptides of the class bacillicymycin from Bacillus subtilis RLID 12.1. Antimicrob. Agents Chemother. 62:e01457-17. doi: 10.1128/AAC.01457-17

Raman, N., Lee, M. R., Lynn, D. M., and Palecek, S. P. (2015). Antifungal activity of 16-helical β-peptides against planktonic cells and biofilms of Candida species. Pharmaceuticals 8, 483–503. doi: 10.3390/ph8030483

Rani, P. H., Anandharaj, M., Hema, S., Deepika, R., and David Ravindran, A. (2016). Purification of antilisterial peptide (Subtilosin A) from novel Bacillus tequilensis F9 and demonstrate their pathogen invasion protection ability using human carcinoma cell line. Front. Microbiol. 7:1910. doi: 10.3389/fmicb.2016.01910

Rasch, M., and Knuschel, S. (1998). Variations in tolerance of Listeria monocytogenes to nisin, pediocin PA-1 and bacvaricin A. Lett. Appl. Microbiol. 27, 275–278.

Reen, F. J., Gutiérrez-Barranquero, J. A., Dobson, A. D., Adams, C., and O’Gara, F. (2015). Emerging concepts promising new horizons for marine biodiscovery and synthetic biology. Mar. Drugs 13, 2924–2954. doi: 10.3390/md13052924

Ren, H., Biswas, S., Ha, S., van der Donk, W. A., and Zhao, H. (2018). Rapid discovery of glycocins through pathway refactoring in Escherichia coli. ACS Chem. Biol. 13, 2996–2972. doi: 10.1021/acscbg.8b00599

Sharma, D., Mandal, S. M., and Manhas, R. K. (2014). Purification and characterization of a novel lipopeptide from Streptomyces amritsarensis sp. nov. active against mericillin-resistant Staphylococcus aureus. AMB Express 4:50. doi: 10.1186/s13568-014-0050-y

Singh, P. K., Sharma, S., Kumari, A., and Korpole, S. (2014). A non-pediocin low molecular weight antimicrobial peptide produced by Pediococcus pentosaceus.
strains IE-3 shows increased activity under reducing environment. BMC Microbiol. 14:226. doi: 10.1186/s12866-014-0226-2

Smibert, R. M., and Krieg, N. R. (1994). "Phenotypic characterization," in Methods for General and Molecular Bacteriology, eds P. Gerhardt, R. G. Murray, W. A. Wood, and N. R. Krieg (Washington, DC: American Society for Microbiology), 607–654. doi: 10.1002/food.1996040022

Strieker, M., and Marahiel, M. A. (2009). The structural diversity of acidic lipopeptide antibiotics. ChemBioChem 4, 607–616. doi: 10.1002/cbic.200800546

Suresh, K., Mayilraj, S., and Chakrabarti, T. (2006). Effluviibacterroseus gen. nov. sp. nov., isolated from muddy water, belonging to the family "Flexibacteraceae". Int. J. Syst. Evol. Microbiol. 56, 1703–1707.

Tareq, F. S., Lee, M. A., Lee, H. S., Lee, J. S., Lee, Y. J., and Shin, H. J. (2014). Gageostatins A-C, antimicrobial linear lipopeptides from a marine Bacillus subtilis. Mar. Drugs 12, 871–885. doi: 10.3390/md12020871

Villegas-Escobar, V., Ceballos, L., Mira, J. J., Argel, L. E., Orduz Peralta, S., and Romero-Tabarez, M. (2013). Fengycin c produced by Bacillus subtilis EA-CB0015. J. Nat. Prod. 76, 503–509. doi: 10.1021/np300574v

Wang, S., Huang, S., Ye, Q., Zeng, X., Yu, H., and Qi, D. (2018). Prevention of cyclophosphamide-induced immunosuppression in mice with the antimicrobial peptide sublancin. J. Immunol. Res. 2018:4353580. doi: 10.1155/2018/4353580

Wang, S., Wang, Q., Zeng, X., Ye, Q., Huang, S., Yu, H., et al. (2017). Use of the antimicrobial peptide sublancin with combined antibacterial and immunomodulatory activities to protect against methicillin-resistant Staphylococcus aureus infection in mice. J. Agric. Food Chem. 65, 8595–8605. doi: 10.1021/acs.jafc.7b02592

Wong, D., Nielsen, T. B., Bonomo, R. A., Pantapalangkoor, P., Luna, B., and Spellberg, B. (2017). Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clin. Microbiol. Rev. 30, 409–447. doi: 10.1128/CMR.00058-16

Wu, C., Biswas, S., Garcia De Gonzalez, C. V., and van der Donk, W. A. (2019). Investigations into the mechanism of action of sublancin. ACS Infect. Dis. 5, 454–459. doi: 10.1021/acssinfecdis.8b0320

Yoon, S. H., Ha, S. M., Lim, J., Kwon, S., and Chun, J. (2017). A large-scale evaluation of algorithms to calculate average nucleotide identity. Antonie Leeuwenhoek 110, 1281–1286. doi: 10.1007/s10482-017-0844-4

Youssef, N. H., Dunacn, K. E., Nagle, D. P., Savage, K. N., Knapp, R. M., and McInerney, M. J. (2004). Comparison of methods to detect biosurfactant production by diverse microorganism. J. Microbiol. Methods 56, 339–347. doi: 10.1016/j.mimet.2003.11.001

Zhang, L., and Sun, C. (2018). Fengycins, cyclic lipopeptides from marine Bacillus subtilis strains, kill the plant-pathogenic fungus Magnaporthe grisea by inducing reactive oxygen species production and chromatin condensation. Appl. Environ. Microbiol. 84:e00445-18. doi: 10.1128/AEM.00445-18

Zheng, L., Chen, H., Han, X., Lin, W., and Yan, X. (2005). Antimicrobial screening and active compound isolation from marine bacterium Nj6 3-1 associated with the sponge Hymeniacidon perleve. World J. Microbiol. Biotechnol. 21, 201–206. doi: 10.1007/s11274-004-3318-6

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Sharma, Singh, Baidnara, Sharma, Khatri, Grover, Patil and Korpole. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.